JPS6259118B2 - - Google Patents
Info
- Publication number
- JPS6259118B2 JPS6259118B2 JP14660281A JP14660281A JPS6259118B2 JP S6259118 B2 JPS6259118 B2 JP S6259118B2 JP 14660281 A JP14660281 A JP 14660281A JP 14660281 A JP14660281 A JP 14660281A JP S6259118 B2 JPS6259118 B2 JP S6259118B2
- Authority
- JP
- Japan
- Prior art keywords
- glycyrrhizin
- solution
- urea
- water
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 67
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 67
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 67
- 239000004378 Glycyrrhizin Substances 0.000 claims description 66
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 66
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 66
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 21
- 239000004202 carbamide Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 17
- 239000004299 sodium benzoate Substances 0.000 claims description 17
- 235000010234 sodium benzoate Nutrition 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 239000003002 pH adjusting agent Substances 0.000 claims description 4
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229940010454 licorice Drugs 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 239000000243 solution Substances 0.000 description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000003929 acidic solution Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000003513 alkali Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000003204 osmotic effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229930002879 flavonoid pigment Natural products 0.000 description 1
- 150000004638 flavonoid pigments Chemical class 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- -1 glycyrrhizin monopotassium salt Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Description
本発明は常温において、有用なグリチルリチン
溶液を調製する方法に関するものである。
甘草有効成分グリチルリチンは優れたる抗炎症
作用を有し、従来抗アレルギー剤として重要視さ
れてきた。近時慢性肝炎疾患の肝機能改善に顕著
な薬効を奏することが内外で実証され、又γ−イ
ンターフエロンの誘起剤として注目されている。
従つて今日益々その安定なるグリチルリチン製剤
の量産が要望されている。
こゝに簡単にグリチルリチン及びその塩の溶状
について述べる。グリチルリチン(グリチルリチ
ン酸)はグリチルレチン酸のジグルクロン酸抱合
体で、三塩基酸である。これは希エタノールに僅
溶、エーテルに不溶、高融点で、水には熱時でも
極めて難溶性のものである。グリチルリチンのモ
ノ塩はグリチルリチンと同様に酸性を呈し、水中
ではその表面が寒天状を呈し、常温では水に溶け
難い。高温では溶解するが、温度低下と共にモノ
塩がゲル状に析出する。しかしジ及びトリ塩にな
ると水に可溶性になる。グリチルリチンは酸分解
でグリチルレチン酸とグルクロン酸に分解し、ア
ルカリと加温すると黄変する。
この様に水に難溶性のグリチルリチン又はその
モノ塩を原料として常温においてグリチルリチン
溶液を調製することは、なかなか簡単にはゆかな
い。通常グリチルリチンの使用濃度(0.1〜2.0
%)の水と適正量のアルカリ中和剤とを用いて撹
拌加熱し、之に等張化剤を添加することになる。
グリチルリチンとアルカリとの反応は、温時又は
高濃度の場合、特に過剰のアルカリが接触した場
合、微量に混有するフラボノイド色素のため着色
することがあるので細心の注意が要求される。現
在グリチルリチン溶液の原料となるものは純度の
高いグリチルリチン及びそのモノ塩(アンモニウ
ム、ナトリウム、カリウム)であつて、可溶性ジ
アルカリ塩、トリアルカリ塩は製造時のアルカリ
処理のため着色せるのが多いので医薬用としては
用いられない。又グリチルリチン溶液に、特に熱
に不安定な例えばグルクロン酸、アスコルビン酸
或いはシステインの様な薬物を配合する場合は、
細心の注意を払わねば経時的に沈澱析出、着色の
現象がおきるおそれがある。
発明者らは、これらの難点を除くため上記の変
質を伴う傾向がある加熱行程を避け、一切常温下
でグリチルリチン溶液を簡易に量産化しうる方法
として、極めて有利であるところの主薬の溶解安
定剤について研究を重ねた。その結果グリチルリ
チン又はその塩の溶解剤としては尿素及び安息香
酸ナトリウムが最も適切であることがわかつた。
即ちこれらの溶解剤の高濃度の溶液を作り、之
に難溶性のグリチルリチン又はその塩を加えると
常温で容易に溶解して、一定の酸性溶液が得られ
る。次いで適正なるPH調整剤にてアルカリ側にな
らぬ様にPHを6〜7に調整し、必要に応じて所定
のグリチルリチンの濃度(0.1〜2.0%)に水にて
希釈すれば本調製法の目的を達成することができ
る。
特にこの両溶解剤は後述する如く、適度の濃度
の量を使用することによつて(尿素1〜3%)安
息香酸ナトリウム1〜3%)グリチルリチン溶液
の等張性が得られるので、特に等張化剤を添加す
る必要がない。しかもこの両溶解剤は生体に極め
て安全であり、医薬品の添加剤としてのその許容
量が大きい。
次に尿素及び安息香酸ナトリウムのグリチルリ
チン化合物に対する溶解能(大約)を表記すると
次の如し。
The present invention relates to a method for preparing a useful glycyrrhizin solution at room temperature. Glycyrrhizin, an active ingredient in licorice, has an excellent anti-inflammatory effect and has been considered important as an anti-allergy agent. Recently, it has been demonstrated both domestically and internationally that it has a remarkable medicinal effect in improving liver function in chronic hepatitis diseases, and it is also attracting attention as an inducer of γ-interferon.
Therefore, there is an increasing demand for the mass production of stable glycyrrhizin preparations. Here, we will briefly discuss the solubility of glycyrrhizin and its salts. Glycyrrhizin (glycyrrhizinic acid) is a diglucuronic acid conjugate of glycyrrhetinic acid and is a tribasic acid. It is slightly soluble in dilute ethanol, insoluble in ether, has a high melting point, and is extremely sparingly soluble in water even when heated. Like glycyrrhizin, the monosalt of glycyrrhizin is acidic, its surface takes on an agar-like appearance in water, and it is difficult to dissolve in water at room temperature. Although it dissolves at high temperatures, the monosalt precipitates out in the form of a gel as the temperature decreases. However, di- and tri-salts become soluble in water. Glycyrrhizin decomposes into glycyrrhetinic acid and glucuronic acid by acid decomposition, and turns yellow when heated with an alkali. It is not easy to prepare a glycyrrhizin solution at room temperature using glycyrrhizin or its monosalt, which is sparingly soluble in water, as a raw material. Usual concentration of glycyrrhizin (0.1-2.0
%) of water and an appropriate amount of an alkali neutralizing agent are stirred and heated, and an isotonic agent is added thereto.
When reacting glycyrrhizin with an alkali at a high temperature or at a high concentration, and especially when it comes into contact with an excessive amount of alkali, it may cause coloration due to trace amounts of flavonoid pigments, so careful attention is required. Currently, the raw materials for glycyrrhizin solutions are highly pure glycyrrhizin and its monosalts (ammonium, sodium, potassium), and soluble dialkali salts and trialkali salts are often colored due to alkali treatment during production, so they are not used for pharmaceuticals. It is not used for any purpose. In addition, when adding heat-labile drugs such as glucuronic acid, ascorbic acid, or cysteine to the glycyrrhizin solution,
If extreme care is not taken, there is a risk of precipitation and coloring occurring over time. In order to eliminate these difficulties, the inventors have developed a solution stabilizer for the main ingredient that is extremely advantageous as a method that can easily mass-produce glycyrrhizin solutions at room temperature, avoiding the heating process that tends to involve the above-mentioned deterioration. I've done a lot of research on this. As a result, it was found that urea and sodium benzoate are the most suitable solubilizers for glycyrrhizin or its salt. That is, if a highly concentrated solution of these solubilizers is prepared and sparingly soluble glycyrrhizin or its salt is added thereto, it will be easily dissolved at room temperature to obtain a certain acidic solution. Next, adjust the pH to 6 to 7 using an appropriate pH adjuster to prevent it from becoming alkaline, and if necessary, dilute with water to the specified glycyrrhizin concentration (0.1 to 2.0%). Able to achieve purpose. In particular, as described below, by using these two solubilizers in appropriate concentrations (urea 1-3%, sodium benzoate 1-3%), isotonicity of the glycyrrhizin solution can be obtained. There is no need to add a tonicifying agent. Furthermore, both of these solubilizers are extremely safe for living organisms, and have a large tolerance as additives for pharmaceuticals. Next, the solubility (approximate) of urea and sodium benzoate for glycyrrhizin compounds is expressed as follows.
【表】
尿素溶液の主薬グリチルリチンに対する溶解能
を高めるためには尿素の濃度をこくすることが必
要である。飽和溶液に近い50%と33.3%との溶解
能は上表の通り大きな差がある。33.3%以下の濃
度のものでは本法の目的には不適当である。一方
安息香酸ナトリウム水溶液の溶解能は尿素と同じ
様な傾向があるが、尿素にみられるような濃度の
差に大きな影響はない、グリチルリチンを除けば
低濃度のものも溶解剤として使用出来る。
本発明は上記の如き確認にもとずきグリチルリ
チン又はその塩を溶解するのに一切加熱処理を行
わず、常温において有用なるグリチルリチン溶液
を調製する工業的製法を提供しようとするもので
ある。
この目的を達するために講じた本発明の要旨と
するところは、特許請求の範囲に示す如く、グリ
チルリチン又はその塩を常温において尿素又は安
息香酸ナトリウムの如き溶解剤の水溶液に溶解
し、ここに濃厚なる主薬の酸性溶液を得、次にPH
調整剤にて円滑にPH6.0〜7.0となし、之を所定の
濃度に希釈することを特徴とするものである。な
ほPH調整剤としては通常炭酸アルカリ、炭酸水素
アルカリ、水酸化アルカリ、クエン酸ナトリウ
ム、リン酸ニナトリウム、安息香酸ナトリウム及
びそれらの水溶液が用いられる。
次に本法について具体的に説明する。
〜尿素を用いる方法〜
実施例に示す如く尿素150gを水150mlに溶解
すると殆ど飽和溶液で、50W/W%264mlとな
る。前記の表からみてグリチルリチン20gはよく
溶けて、先ずグリチルリチンの酸性尿素溶液とな
る。PHは約3.4である。之にPH調整剤として1N水
酸化ナトリウム液を徐々に加えてPH6.5前後とす
る。これによつてグリチルリチンとアルカリ剤と
の直接加温中和による主薬の変質を防止すること
ができる。次いで水にて希釈して1とすれば2
%、10とすれば0.2%グリチルリチン溶液が得
らる。
原料をグリチルリチンモノアンモニウム塩を使
用する場合は、実施例の如くグリチルリチンの
約1.02倍量のアンモニウム塩を用いる。又グリチ
ルリチンモノカリウム塩を使用する場合、実施例
の如くグリチルリチンの約1.046倍量のカリウ
ム塩を用いる。実施例、の如く夫々尿素の飽
和溶液に溶解し、常温において濃厚なる酸性溶液
となし、前者の場合はアンモニア試液、後者は
1N水酸化カリウム液にてPHを調製し、PH約6.5と
なし、これらを水にて希釈して0.2%、0.5%グリ
チルリチン溶液が得らる。
〜安息香酸ナトリウムを用いる方法〜
グリチルリチン20gを原料とし、0.2%グリチ
ルリチン溶液10を製する場合、実施例に示す
如く、グリチルリチン20gを40W/V%安息香酸
ナトリウム溶液375mlに溶解する。表記した如
く、容易に溶解してグリチルリチンの安息香酸ナ
トリウム溶液が得られる。この場合その液性は溶
解剤の液性によつて調整されてPH5.4となる。次
いで、1N水酸化ナトリウム液でPHを6.5前後に調
整し水にて希釈して10とすれば0.2%グリチル
リチン溶液が得らる。次にグリチルリチンモノナ
トリウムを原料として0.2%グリチルリチン溶液
10を調整する場合は、実施例に示す如くグリ
チルリチンの1.026倍のグリチルリチンモノナト
リウム20.5gを用い40W/V%安息香酸ナトリウ
ム液550mlに溶解すると澄明なる弱酸性液(PH
5.8)を得る。之を上記と同様に1N水酸化ナトリ
ウム液にてPHを約6.5前後に調整し、水にて希釈
し10とすれば約PH6.6の0.2%グリチルリチン溶
液が得られる。
次に実施例によつて得られた各種グリチルリチ
ン溶液の主薬、溶解薬の各濃度及びそれら溶液の
生理食塩液に対する浸透圧比を示すと以下の様で
ある。
実施例0.2%グリチルリチン、1.5%尿素……
浸透圧比0.73;実施例0.2%グリチルリチン、
2%尿素……浸透圧比1.04;実施例0.5%グリ
チルリチン、2%尿素……浸透圧比1.05;実施例
0.2%グリチルリチン、1.5%安息香酸ナトリウ
ム……浸透圧比……0.64;実施例0.2%グリチ
ルリチン、2.2%安息香酸ナトリウム……浸透圧
比1.08。
使用されるグリチルリチンの濃度が0.1〜2.0%
の場合、溶解薬の濃度は上記以外の広範囲の濃度
がとられる。実施例の様な溶液が調製され
た場合、その生理食塩液に対する浸透圧比は1.0
強となり、溶解剤が等張化剤の働きをなし、等張
化のため特に他の薬剤を添加する必要がない。
本法によつて得らるゝ効果を述べると次の様で
ある。グリチルリチン又はその塩を常温で高濃度
に仕込む事が出来る事は、小規模で製品の量産化
が可能となり、工業的方法として有利であると同
時に加熱行程が省かれるので品質の損失がなく、
製品の均一性が保たれる。殊に熱い弱い他の薬物
を配合せんとする場合有利である。本法によつて
溶解効果をもたらす尿素又は安息香酸ナトリウム
は溶解剤として役立つのみならず等張化剤として
の効果があり、製品の安全性が確保出来る。
実施例
尿素150gを水150mlに溶解し、これに常温にお
いてグリチルリチン20gを少し宛加えると、暫時
にして透明なさらさらした酸性溶液(PH3.4)が
得られる。次いで1N水酸化ナトリウム液約70ml
を徐々に加え、PHを6.5前後とし、之を水にて希
釈し10にすれば0.2%グリチルリチン溶液(PH
6.8)が得られる。
実施例
尿素200gを水200mlに溶解し、グリチルリチン
モノアンモニウム20.4gを常温において徐々に加
えると澄明なる酸性溶液を(PH4.2)を得る。次
いでアンモニア試液を注意深く添加してPHを6.5
前後とし、これを水にて希釈し1とすれば2%
溶液、さらに10にすれば0.2%グリチルリチン
溶液(PH6.8)を得る。
実施例
尿素160gを水160mlに溶解し、これに常温にお
いてグリチルリンモノカリウム41.8gを徐々に加
えると暫時にして澄明なさらさらした酸性溶液
(PH4.5)が得られる。次いで1N水酸化カリウム
液約90mlを注意深く加え、PHを6.5前後とし、之
を水にて希釈して8とすればPH6.8の0.5%グリ
チルリチン溶液が得られる。
実施例
40W/V%安息香酸ナトリウム溶液375mlをと
り、之にグリチルリチン20gを徐々に加えると暫
時にして澄明な酸性溶液(PH5.4)となる。之に
1N水酸化ナトリウム液約50mlを添加しPHを6.5前
後となし、次いで水にて希釈し10とすれば0.2
%グリチルリチン溶液(PH6.6)が得られる。
実施例
40W/V%安息香酸ナトリウム溶液550mlをと
り、これに常温にてグリチルリチンモノナトリウ
ム20.5gを加えると暫時にして澄明な酸性溶液
(PH5.8)となる。次いで1N水酸化ナトリウム液
約46mlを添加し、PH6.5前後とし、水にて希釈し
て10にすれば0.2%グリチルリチン溶液(PH
6.8)が得らる。[Table] In order to increase the dissolution ability of the urea solution for the main drug glycyrrhizin, it is necessary to increase the concentration of urea. As shown in the table above, there is a large difference in solubility between 50% and 33.3%, which are close to saturated solutions. Concentrations below 33.3% are unsuitable for the purpose of this method. On the other hand, the solubility of sodium benzoate aqueous solution tends to be similar to that of urea, but there is no significant difference in concentration as seen with urea, and with the exception of glycyrrhizin, low concentrations can also be used as a solubilizing agent. Based on the above-mentioned confirmation, the present invention aims to provide an industrial manufacturing method for preparing a useful glycyrrhizin solution at room temperature without performing any heat treatment to dissolve glycyrrhizin or its salt. The gist of the present invention, taken to achieve this object, is, as shown in the claims, that glycyrrhizin or its salt is dissolved in an aqueous solution of a solubilizing agent such as urea or sodium benzoate at room temperature, and then concentrated. Obtain an acidic solution of the main drug, then adjust the PH
It is characterized by smoothly adjusting the pH to 6.0 to 7.0 with a regulator and diluting it to a predetermined concentration. As the pH adjuster, alkali carbonate, alkali hydrogen carbonate, alkali hydroxide, sodium citrate, disodium phosphate, sodium benzoate, and aqueous solutions thereof are usually used. Next, this method will be explained in detail. ~Method using urea~ As shown in the example, when 150 g of urea is dissolved in 150 ml of water, it becomes an almost saturated solution, with a concentration of 50 W/W%, 264 ml. Judging from the above table, 20g of glycyrrhizin dissolves well and first becomes an acidic urea solution of glycyrrhizin. PH is approximately 3.4. Gradually add 1N sodium hydroxide solution as a pH adjuster to adjust the pH to around 6.5. This can prevent deterioration of the main drug due to direct heating neutralization of glycyrrhizin and an alkaline agent. Then dilute it with water and make it 1, then 2
%, 10, a 0.2% glycyrrhizin solution will be obtained. When using glycyrrhizin monoammonium salt as a raw material, the ammonium salt is used in an amount approximately 1.02 times that of glycyrrhizin as in the example. In addition, when using glycyrrhizin monopotassium salt, the amount of potassium salt is about 1.046 times that of glycyrrhizin as in the example. As shown in the examples, each is dissolved in a saturated solution of urea to form a concentrated acidic solution at room temperature.
Adjust the pH with 1N potassium hydroxide solution to about 6.5, and dilute this with water to obtain 0.2% and 0.5% glycyrrhizin solutions. ~Method using sodium benzoate~ When preparing 0.2% glycyrrhizin solution 10 using 20 g of glycyrrhizin as a raw material, 20 g of glycyrrhizin is dissolved in 375 ml of a 40 W/V% sodium benzoate solution as shown in the example. As shown, it is easily dissolved to obtain a sodium benzoate solution of glycyrrhizin. In this case, the liquid property is adjusted by the liquid property of the dissolving agent and becomes PH5.4. Next, adjust the pH to around 6.5 with 1N sodium hydroxide solution and dilute with water to a total of 10 to obtain a 0.2% glycyrrhizin solution. Next, 0.2% glycyrrhizin solution using glycyrrhizin monosodium as raw material.
10, as shown in the example, use 20.5 g of glycyrrhizin monosodium, which is 1.026 times that of glycyrrhizin, and dissolve it in 550 ml of 40 W/V% sodium benzoate solution to obtain a clear weakly acidic solution (PH
5.8). In the same manner as above, adjust the pH to around 6.5 with 1N sodium hydroxide solution, and dilute with water to 10 to obtain a 0.2% glycyrrhizin solution with a pH of about 6.6. Next, the concentrations of the main drug and solubilizing agent in the various glycyrrhizin solutions obtained in the Examples and the osmotic pressure ratios of these solutions to physiological saline are as follows. Example 0.2% glycyrrhizin, 1.5% urea...
Osmotic pressure ratio 0.73; Example 0.2% glycyrrhizin,
2% urea...osmotic pressure ratio 1.04; Example 0.5% glycyrrhizin, 2% urea...osmotic pressure ratio 1.05; Example
0.2% glycyrrhizin, 1.5% sodium benzoate...osmotic pressure ratio...0.64; Example 0.2% glycyrrhizin, 2.2% sodium benzoate...osmotic pressure ratio 1.08. The concentration of glycyrrhizin used is 0.1-2.0%
In this case, the concentration of the lytic agent may range over a wide range other than those listed above. When a solution like the example is prepared, its osmotic pressure ratio to physiological saline is 1.0.
The solubilizing agent acts as a tonicity agent, and there is no need to add other drugs for isotonicity. The effects obtained by this method are as follows. Being able to prepare glycyrrhizin or its salt at a high concentration at room temperature makes it possible to mass-produce products on a small scale, which is advantageous as an industrial method, and at the same time eliminates the heating process, so there is no loss of quality.
Product uniformity is maintained. This is particularly advantageous when other hot and weak drugs are to be combined. The urea or sodium benzoate that brings about the dissolution effect by this method not only serves as a solubilizing agent but also as an isotonic agent, ensuring product safety. Example When 150 g of urea is dissolved in 150 ml of water and a small amount of 20 g of glycyrrhizin is added to the solution at room temperature, a clear, free-flowing acidic solution (PH3.4) is obtained in a short period of time. Next, add approximately 70ml of 1N sodium hydroxide solution.
0.2% glycyrrhizin solution (PH
6.8) is obtained. Example: Dissolve 200 g of urea in 200 ml of water and gradually add 20.4 g of glycyrrhizin monoammonium at room temperature to obtain a clear acidic solution (PH4.2). Then carefully add ammonia TS to bring the pH to 6.5.
If you dilute this with water and make it 1, it will be 2%.
If the solution is further increased to 10, a 0.2% glycyrrhizin solution (PH6.8) will be obtained. Example When 160 g of urea is dissolved in 160 ml of water and 41.8 g of glycyrrhine monopotassium is gradually added thereto at room temperature, a clear and free-flowing acidic solution (PH4.5) is obtained in a short period of time. Next, carefully add about 90 ml of 1N potassium hydroxide solution to adjust the pH to around 6.5, and dilute this with water to a pH of 8 to obtain a 0.5% glycyrrhizin solution with a pH of 6.8. Example 4 375 ml of 0W/V% sodium benzoate solution is taken and 20 g of glycyrrhizin is gradually added thereto, resulting in a clear acidic solution (PH5.4) in a short period of time. To that
Add about 50ml of 1N sodium hydroxide solution to adjust the pH to around 6.5, then dilute with water to make it 10, then 0.2
% glycyrrhizin solution (PH6.6) is obtained. Example 4 Take 550 ml of a 0W/V% sodium benzoate solution and add 20.5 g of glycyrrhizin monosodium to it at room temperature, which instantly turns into a clear acidic solution (PH5.8). Next, add about 46 ml of 1N sodium hydroxide solution to adjust the pH to around 6.5, and dilute with water to a concentration of 10 to create a 0.2% glycyrrhizin solution (PH
6.8) is obtained.
Claims (1)
常温において尿素又は安息香酸ナトリウム及びPH
調整剤を作用させることを特徴とする有用なるグ
リチルリチン溶液の調製法。 2 尿素の濃厚溶液にグリチルリチン又はその塩
を常温において溶解し、得らるる酸性濃厚溶液を
PH調整剤にて約中性溶液とし、所定の濃度に水に
て希釈することを特徴とする特許請求の範囲第1
項記載の有用なるグリチルリチン溶液の調製法。 3 安息香酸ナトリウムの濃厚溶液にグリチルリ
チン又はその塩を常温において溶解し、得らるる
酸性濃厚溶液をPH調整剤にて約中性溶液とし、所
定の濃度に水にて希釈することを特徴とする特許
請求の範囲第1項記載の有用なるグリチルリチン
溶液の調製法。[Claims] 1. Glycyrrhizin, an active ingredient of licorice, or a salt thereof,
Urea or sodium benzoate and PH at room temperature
1. A useful method for preparing a glycyrrhizin solution, characterized by the action of a regulator. 2 Dissolve glycyrrhizin or its salt in a concentrated solution of urea at room temperature, and dissolve the resulting acidic concentrated solution.
Claim 1, characterized in that the solution is made approximately neutral with a pH adjuster and diluted with water to a predetermined concentration.
Method for preparing useful glycyrrhizin solutions as described in Section 1. 3 Glycyrrhizin or its salt is dissolved in a concentrated solution of sodium benzoate at room temperature, the resulting acidic concentrated solution is made into an approximately neutral solution with a PH adjuster, and the solution is diluted with water to a predetermined concentration. A method for preparing a useful glycyrrhizin solution according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14660281A JPS5849310A (en) | 1981-09-17 | 1981-09-17 | Preparation of useful glycyrrhizin solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14660281A JPS5849310A (en) | 1981-09-17 | 1981-09-17 | Preparation of useful glycyrrhizin solution |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5849310A JPS5849310A (en) | 1983-03-23 |
JPS6259118B2 true JPS6259118B2 (en) | 1987-12-09 |
Family
ID=15411430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14660281A Granted JPS5849310A (en) | 1981-09-17 | 1981-09-17 | Preparation of useful glycyrrhizin solution |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5849310A (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2616800B1 (en) * | 1987-06-16 | 1990-01-12 | Pernod Ricard | PRODUCTION OF A BGLUCURONIDASE TYPE ENZYME, HYDROLYSIS OF GLYCYRRHIZINE AND PRODUCTION OF 18 B-GLYCYRRHETINIC ACID |
AU2004263036B2 (en) * | 2003-08-12 | 2010-06-03 | Nippon Zoki Pharmaceutical Co., Ltd. | Glycyrrhizin high-concentration preparation |
CN104072572B (en) * | 2014-07-21 | 2016-08-24 | 江苏天晟药业有限公司 | A kind of Monosodium glycyrrhetin and preparation method thereof |
-
1981
- 1981-09-17 JP JP14660281A patent/JPS5849310A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5849310A (en) | 1983-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4749707A (en) | Citric acid salt of (+) vinpocetine | |
KR930001915A (en) | Pharmaceutical Compositions Suitable for the Treatment of Pancreatic Fibrosis and Chronic Pain Syndrome | |
DE3151196A1 (en) | METHOD FOR PRODUCING EASILY SOLUBLE 5-AMINOSALICYL ACID MEDICAL PREPARATIONS | |
FI120080B (en) | Pharmaceutical compositions with antibiotic activity | |
JPH0154338B2 (en) | ||
US2848366A (en) | Non-hydrated ferrous fumarate and hematinic composition thereof | |
JPS6259118B2 (en) | ||
IE51568B1 (en) | Vincamine saccharinate and pharmaceutical compositions containing same | |
US7109373B2 (en) | Creatine salts and method of making same | |
US3767803A (en) | Stable aqueous pyritinol solutions | |
US3751564A (en) | Process for preparing scleroprotein-alkyl thiosulfate agents for the care of the hair | |
GB1498160A (en) | Agent for skin treatment and a wet diaper prepared therewith | |
US2434625A (en) | Preparation of alkali metal ascorbates | |
US2388261A (en) | Riboflavin solution | |
US3809759A (en) | Pharmaceutical composition for treating mental fatigue containing arginine-potassium phospho citro glutamate and method of using the same | |
US3542929A (en) | Chemotherapeutic compositions useful in animal detoxification | |
DE2706841C2 (en) | ||
US2449041A (en) | Riboflavin solutions | |
GB1564135A (en) | Readily-assimilatable highly-soluble calcium and/or magnesium organic salts | |
JPH026335B2 (en) | ||
JPH0414646B2 (en) | ||
JPS60163897A (en) | Ursodeoxycholic acid meglumine salt and its injection | |
JPS61218522A (en) | Iron hydroxide colloidal solution stable in neutrality/ weak alkalinity | |
US2261188A (en) | Stabilized form of vitamin b6 and process of preparing the same | |
SE7700108L (en) | ANTIMICROBIAL CLEANER |